Table 1.
Patients characteristics.
| Variable | Level | Responder (n = 29) | Non-responder (n = 22) |
|---|---|---|---|
| Age | Median | 68 (43–78) | 69 (44–74) |
| Sex | Male | 23 (79.3%) | 15 (68.2%) |
| Female | 6 (20.7%) | 7 (31.8%) | |
| Smoking | Yes | 17 (58.6%) | 13 (59.1%) |
| No | 5 (17.2%) | 8 (36.3%) | |
| Unknown | 7 (24.1%) | 1 (4.6%) | |
| Clinical stage | cT2 | 20 (68.9%) | 10 (45.4%) |
| cT3 | 9 (31.1%) | 11 (50%) | |
| cT4 | 0 | 1 (4.6%) | |
| Histology | Pure UC | 28 (96.6%) | 21 (95.4%) |
| UC + variant histology | 1 (3.4%) | 1 (4.6%) | |
| TURBT | Yes | 11 (37.9%) | 6 (27.3%) |
| No | 18 (62.1%) | 16 (72.7%) | |
| NAC regimen | GC/CaG | 25 (86.2%) | 15 (68.2%) |
| MVAC | 4 (13.8%) | 7 (31.8%) | |
| Pathological stage | pT0 | 12 (41.4%) | 0 |
| pTis/1 | 17 (58.6%) | 0 | |
| pT2 | 0 | 10 (45.4%) | |
| ≥pT3 | 0 | 12 (54.6%) |
UC urotherial carcinoma, TURBT trans-urethral resection of bladder cancer, NAC neoadjuvant chemotherapy, GC gemcitabine + cisplatin, CaG carboplatin + gemcitabine, MVAC methotrexate + vinblastine + doxorubicin (adriamycin) + cisplatin.